WallStSmart

DaVita HealthCare Partners Inc (DVA)vsCharming Medical Limited Class A Ordinary Shares (MCTA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 291300% more annual revenue ($14.01B vs $4.81M). DVA leads profitability with a 6.0% profit margin vs -0.5%. DVA trades at a lower P/E of 15.6x. DVA earns a higher WallStSmart Score of 70/100 (B).

DVA

Strong Buy

70

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 7.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22

MCTA

Avoid

11

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 4.0Quality: 5.0
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAOvervalued (-13.0%)

Margin of Safety

-13.0%

Fair Value

$127.66

Current Price

$181.55

$53.89 premium

UndervaluedFair: $127.66Overvalued

Intrinsic value data unavailable for MCTA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA5 strengths · Avg: 9.6/10
PEG RatioValuation
0.4510/10

Growing faster than its price suggests

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

EPS GrowthGrowth
55.8%10/10

Earnings expanding 55.8% YoY

Debt/EquityHealth
-14.0910/10

Conservative balance sheet, low leverage

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

MCTA0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
6.0%3/10

6.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

MCTA4 concerns · Avg: 2.8/10
Market CapQuality
$445.55M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
4.9%3/10

Operating margin of 4.9%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
419.4x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.

Bull Case : MCTA

MCTA has a balanced fundamental profile.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : MCTA

The primary concerns for MCTA are Market Cap, Operating Margin, Piotroski F-Score. A P/E of 419.4x leaves little room for execution misses.

Key Dynamics to Monitor

DVA profiles as a value stock while MCTA is a turnaround play — different risk/reward profiles.

DVA is growing revenue faster at 5.2% — sustainability is the question.

DVA generates stronger free cash flow (320M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (70/100 vs 11/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Charming Medical Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Charming Medical Limited, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. The company is headquartered in Causeway Bay, Hong Kong.

Want to dig deeper into these stocks?